Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter för dermatit, med undantag av kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - denguefeber - vacciner - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 och 4. användning av dengvaxia bör ske i enlighet med officiella rekommendationer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningit, meningokock - vacciner - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) är indicerat för primär- och boostervaccination vaccination av spädbarn och småbarn från sex veckors ålder mot difteri, stelkramp, kikhosta, hepatit b, polio och invasiva sjukdomar orsakade av haemophilus influenzae typ b (hib). användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vacciner - hexyon (dtap-ipv-hb-hib) är indicerat för primär- och boostervaccination vaccination av spädbarn och småbarn från sex veckors ålder mot difteri, stelkramp, kikhosta, hepatit b, polio och invasiva sjukdomar orsakade av haemophilus influenzae typ b (hib). användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vacciner - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 och 5. 1 in product information document). användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sanofi-aventis ab - adenosin - injektionsvätska, lösning - 3 mg/ml - adenosin 3 mg aktiv substans - adenosin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sanofi-aventis ab - adenosin - infusionsvätska, lösning - 3 mg/ml - adenosin 3 mg aktiv substans - adenosin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sanofi-aventis ab - buserelinacetat - nässpray, lösning - 0,1 mg/dos - buserelinacetat 0,105 mg aktiv substans; bensalkoniumklorid hjälpämne - buserelin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sanofi-aventis ab - calciumpolystyrensulfonat - pulver till oral/rektal suspension - calciumpolystyrensulfonat 999,34 mg aktiv substans - polystyrensulfonat